Amgen posts strong first-quarter sales but healthcare reform set to bite
This article was originally published in Scrip
Executive Summary
Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.